OncoSil Medical Ltd (AU:OSL)
ASX:OSL
Want to see AU:OSL full AI Analyst Report?
Top Page
OncoSil Medical Ltd
(Sydney:OSL)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.50
▼(-48.04% Downside)
Action:Reiterated
Date:05/21/26
The score is primarily constrained by weak financial performance—persistent losses and negative cash flows—despite revenue growth and low leverage. Technicals are mixed with a short-term uptick but a longer-term downtrend and negative MACD. Valuation is also pressured by a negative P/E and no dividend yield data.
Positive Factors
Differentiated core product
OncoSil’s core device is a specialized, clinically focused targeted brachytherapy system for locally advanced pancreatic cancer. That product-centric model addresses a high unmet medical need, creating clinical adoption and regulatory barriers that can sustain competitive advantage as adoption grows.
Negative Factors
Persistent unprofitability
Ongoing negative margins indicate the business is not yet generating operating profits from sales and absorbs capital to sustain operations. Without structural margin improvement or scale, persistent losses will require repeated external funding and impair long-term shareholder value.
Read all positive and negative factors
Positive Factors
Negative Factors
Differentiated core product
OncoSil’s core device is a specialized, clinically focused targeted brachytherapy system for locally advanced pancreatic cancer. That product-centric model addresses a high unmet medical need, creating clinical adoption and regulatory barriers that can sustain competitive advantage as adoption grows.
Read all positive factors
OncoSil Medical Ltd (OSL) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$16.12M
Dividend YieldN/A
Average Volume (3M)24.03K
Price to Earnings (P/E)―
Beta (1Y)1.15
Revenue Growth68.30%
EPS Growth40.74%
CountryAU
Employees2
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.95
Shares Outstanding30,697,231
10 Day Avg. Volume8,764
30 Day Avg. Volume24,029
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)4.23
Price to Sales (P/S)11.20
P/FCF Ratio-1.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
OncoSil Medical Ltd Business Overview & Revenue Model
Company Description
OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide. Its lead product is OncoSil, a brachythe...
How the Company Makes Money
null...
OncoSil Medical Ltd Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
30
Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.33M | 1.17M | 516.63K | 367.68K | 231.79K | 213.07K |
| Gross Profit | -3.94M | -1.08M | -993.00K | -1.22M | -6.73M | -748.00K |
| EBITDA | -15.34M | -15.06M | -12.91M | -11.17M | -11.41M | -11.31M |
| Net Income | -12.92M | -15.10M | -11.91M | -11.34M | -10.73M | -10.43M |
Balance Sheet | ||||||
| Total Assets | 7.13M | 7.15M | 6.72M | 11.47M | 13.07M | 14.15M |
| Cash, Cash Equivalents and Short-Term Investments | 2.85M | 5.11M | 4.50M | 9.39M | 11.28M | 12.24M |
| Total Debt | 42.47K | 69.92K | 70.67K | 170.81K | 304.21K | 484.37K |
| Total Liabilities | 3.29M | 4.04M | 1.98M | 1.59M | 1.91M | 2.45M |
| Stockholders Equity | 3.84M | 3.10M | 4.74M | 9.88M | 11.16M | 11.70M |
Cash Flow | ||||||
| Free Cash Flow | -12.91M | -12.08M | -11.02M | -11.37M | -10.12M | -8.87M |
| Operating Cash Flow | -12.91M | -12.06M | -10.82M | -11.32M | -10.11M | -8.82M |
| Investing Cash Flow | -6.56K | -14.96K | -197.06K | -57.82K | -5.83K | -54.00K |
| Financing Cash Flow | 7.35M | 12.73M | 6.13M | 9.49M | 9.16M | 111.25K |
OncoSil Medical Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$24.72M | -1.40 | -98.14% | ― | 14.88% | 35.94% | |
44 Neutral | AU$95.81M | -2.83 | -54.48% | ― | 17.24% | -20.00% | |
44 Neutral | AU$152.45M | -10.00 | -70.29% | ― | ― | -62.15% | |
42 Neutral | AU$16.12M | -1.00 | -372.27% | ― | 68.30% | 40.74% | |
41 Neutral | AU$32.09M | -2.66 | -180.06% | ― | 74.74% | 4.32% | |
41 Neutral | AU$1.95B | -3.16 | -890.76% | ― | -0.80% | -249.48% |
* Healthcare Sector Average
AU:OSL
OncoSil Medical Ltd
0.51
-0.43
-45.97%
AU:CYC
Cyclopharm Limited
0.73
-0.47
-39.17%
AU:MX1
Micro-X Ltd.
0.05
-0.02
-25.00%
AU:EMV
EMvision Medical Devices Ltd.
1.67
-0.04
-2.34%
AU:CBL
Control Bionics Ltd.
0.06
0.03
86.67%
AU:4DX
4DMedical Ltd
3.62
3.36
1292.31%
OncoSil Medical Ltd Corporate Events
OncoSil Updates Market on Change in Substantial Shareholder Interests
Mar 19, 2026
OncoSil Medical Ltd has lodged a notice of change of interests of a substantial holder under Australia’s Corporations Act, indicating an update to a major shareholder’s voting power in the company. The filing, signed by Chief Operating...
OncoSil Director Increases Indirect Stake via Capital Raising
Mar 19, 2026
OncoSil Medical has disclosed a change in director Thomas Duthy’s indirect holdings following his participation in a recent capital raising. Through CIPA Investments Pty Ltd, Duthy acquired 50,537 new shares at $0.68 each, along with 50,537 ...
OncoSil Flags Isolated Administrative Lapse in Director Interest Disclosure
Mar 19, 2026
OncoSil Medical has disclosed a late lodgement of an Appendix 3Y relating to CEO and managing director Nigel Lange, reflecting the lapse and cancellation of certain performance rights and employee loan-funded shares in line with their terms. The c...
OncoSil Medical Securities Reinstated to ASX Quotation
Mar 17, 2026
OncoSil Medical has had its OSLOE class securities reinstated to quotation on the Australian Securities Exchange following confirmation of compliance with ASX Listing Rule 2.5. The resumption of trading restores liquidity and market access for hol...
OncoSil Raises Institutional Capital via Share Placement and Issues Cleansing Notice
Mar 17, 2026
OncoSil Medical has raised new equity by issuing 4,100,470 fully paid ordinary shares at $0.68 each to sophisticated and institutional investors via a placement, providing additional capital to support its interventional oncology business. The sha...
OncoSil Options Register Shows High Concentration Among Institutional Holders
Mar 17, 2026
OncoSil Medical Ltd has disclosed the top 20 holders of its listed options, exercisable at $0.90 and expiring on 30 June 2027, which collectively control 86.28% of the 12,082,126 options on issue. The largest positions are held by institutional no...
OncoSil Medical Seeks ASX Quotation for New Shares and Options
Mar 17, 2026
OncoSil Medical Ltd has applied for quotation on the ASX of 2,951,918 new fully paid ordinary shares and an equal number of deferred options expiring on 30 June 2027. The new securities, issued on 17 March 2026 and linked to a previously announced...
OncoSil seeks ASX quotation for small new share issue
Mar 17, 2026
OncoSil Medical Ltd has applied for quotation on the ASX of 29,509 new ordinary fully paid shares, to be issued on March 17, 2026. The securities are being quoted as part of previously announced transactions, indicating only a minor increase in th...
OncoSil Seeks ASX Quotation for New Tranche of Deferred Options
Mar 17, 2026
OncoSil Medical Ltd has lodged an application with the ASX for quotation of 306,678 deferred options, designated as OSLOE and expiring on June 30, 2027, with an issue date of March 17, 2026. The options are being quoted as securities issued under ...
OncoSil Medical Seeks ASX Quotation for New Shares and Options
Mar 17, 2026
OncoSil Medical has applied to the ASX for quotation of 4,100,470 new ordinary fully paid shares and 8,823,530 deferred options expiring on 30 June 2027. The securities, issued on 17 March 2026 as part of previously announced transactions, expand ...
OncoSil Raises $2m in Fully Subscribed Entitlement Offer to Fund Cancer Device Expansion
Mar 16, 2026
OncoSil Medical has completed a fully subscribed non-renounceable entitlement offer, raising about $2 million including the underwritten portion, to support clinical trials, manufacturing, sales and marketing, market access initiatives and working...
OncoSil shareholders back capital and remuneration resolutions at EGM
Mar 12, 2026
OncoSil Medical Ltd, an interventional oncology specialist focused on device-based treatments for advanced pancreatic cancer, has developed its OncoSil device to deliver targeted radiotherapy via Phosphorous-32 microparticles, and holds marketing ...
ASX Suspends Trading in Specific OncoSil Security Class
Mar 10, 2026
The Australian Securities Exchange has suspended quotation of a specific class of OncoSil Medical Ltd securities, identified by the code OSLOE, under Listing Rule 17.3.4 pending the company’s compliance with Listing Rule 2.5. The suspension ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.